The purpose of this study is to find out whether two different weekly doses of the under-the-skin treatment produce similar levels of the protective protein in the blood compared to the standard doses of the into-the-vein treatment. The study will also look at how safe these treatments are and how well they are tolerated by patients. During the study, participants will first receive the into-the-vein treatment for eight weeks, and then they will switch to receiving the under-the-skin treatment for another eight weeks. Throughout this time, blood samples will be taken regularly to measure the amount of the protective protein in the blood and to see how the body processes the medication. The study will also monitor any side effects that may occur and check lung function to see how well the treatment is working.

Participants in this study will be people between 18 and 80 years old who have been diagnosed with Alpha-1 Antitrypsin Deficiency through genetic testing and have certain breathing difficulties. They may be new to this type of treatment or may already be receiving it, but they will need to stop any other similar treatments during the study. The study will track various measurements including heart rate, blood pressure, breathing rate, temperature, and lung function tests to ensure the safety of participants. Blood tests will also be done to check for any immune system reactions to the treatment and to monitor overall health.

The purpose of the trial is to find out whether early use of depemokimab can lower the number of worsening episodes and keep asthma under better control. Participants will be randomly assigned to receive either the study drug or the placebo, with injections administered in a clinic setting every six months. Over a period that may extend up to three years, they will attend regular visits where doctors will check symptoms, record any serious attacks, and perform simple breathing tests.

During the study, several easy‑to‑understand tools are used: the ACT questionnaire asks about daily symptoms, the AQLQ asks how asthma affects quality of life, and the ACQ-5 measures recent symptom severity. Lung capacity is measured with a test called FEV1, which shows how well the lungs move air in and out, providing an overview of overall lung function. Safety checks are also performed at each visit to monitor how participants tolerate the treatment.

Participants will be divided by age. Those aged 6 to under 18 will be part of a double‑blind phase where neither the participants nor the doctors know who receives the drug or the placebo, followed by an open‑label phase where everyone receives the active medication. Children younger than 6 will start directly with the active drug in an open‑label part. Over the course of the study, researchers will watch for side effects and will measure simple health indicators such as oxygen saturation (SpO2), lung capacity measured as FVC, and the distance walked in six minutes (6‑min walk distance), as well as growth and quality‑of‑life questionnaires.

The purpose of the study is to determine whether stopping the low‑dose medication is not worse than continuing it. Participants are randomly assigned (by chance) to either stop the drug or keep taking it, and they are followed for up to two years. During this time they will have regular clinic visits where they answer quality‑of‑life questionnaires, undergo lung‑function tests such as FEV1 (the amount of air forced out in one second) and FVC (the total amount of air forced out), and have any worsening episodes, called exacerbations, recorded. The study aims to see if patients who stop the medication experience similar health outcomes compared with those who continue it.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

The purpose of the study is to find out whether the added medicine improves lung function better than the dummy inhaler.

Each child will try the low dose, the high dose, and the dummy inhaler in a random order, while continuing their regular BFF inhaler. After each treatment period, lung function will be checked by measuring how much air can be forced out in one second (FEV1). The whole study lasts about three weeks for each treatment period.

The main aim is to see whether the medicine can keep the cancer from coming back compared with the placebo, measured by the length of time patients stay free of disease, known as DFS. Participants will take the study medication for a set period, return for regular check‑ups, and have routine tests such as scans and lab work to monitor their health.

In addition to tracking if the cancer returns, the study will also look at overall survival, which is how long participants live after treatment, referred to as OS, and whether the disease spreads to the CNS. Safety will be watched by recording any side effects using a standard grading system (CTCAE) and by performing simple heart rhythm checks (ECG). The study follows participants for several years to gather this information.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.

Table of contents

• Trial overview
• Condition studied and who can join
• Treatment and comparison
• Study phase and design
• What the trial measures
• Why this trial matters for patients

Trial overview

The available trial data show one authorised study of ZAMPILIMAB in people with idiopathic pulmonary fibrosis, also called IPF^[1]. The study title says it is looking for an efficacious and safe dose of CHF10067, which is identified as zampilimab in the source data^[1].

This is an interventional clinical trial, which means researchers give a study treatment and then measure the results^[1]. The trial is authorised and plans to enrol 235 participants^[1].

Condition studied and who can join

The trial is for participants with idiopathic pulmonary fibrosis^[1]. IPF is a lung disease that causes scarring and can reduce breathing ability; the trial data do not provide more detail about symptoms or disease stage^[1].

The source data do not list full entry rules such as age limits, test results, or previous treatments^[1]. Based on the available information, the target population is people living with IPF^[1].

Treatment and comparison

The study intervention includes ZAMPILIMAB given by intravenous infusion, which means it is delivered into a vein^[1]. The trial data also mention 0.9% sodium chloride aqueous solution for IV infusion as the comparison treatment^[1].

The brief summary says the study is evaluating two dose strengths of CHF10067 and comparing them with placebo in the entire study population^[1]. In simple words, the trial is checking whether different doses work better than a non-active comparison treatment^[1].

Study phase and design

This is a Phase 2 study^[1]. Phase 2 trials usually focus on whether a treatment may help and continue to watch safety in a larger group than early studies, but the source data only confirm the phase and do not add more design details^[1].

The study is listed as interventional and authorised, with an expected enrolment of 235 participants^[1]. The available data do not describe randomisation, masking, or how many study groups there are^[1].

What the trial measures

The primary outcome is measured at Week 24^[1]. The main endpoint is the change from baseline in percent predicted forced vital capacity, or ppFVC, compared with placebo in the whole study population^[1].

Forced vital capacity is a lung function test that shows how much air a person can breathe out after taking a deep breath^[1]. ‘Percent predicted’ means the result is compared with what would be expected for someone of similar age, sex, height, and background^[1].

Why this trial matters for patients

For people with IPF, lung function can slowly get worse over time, so studies that measure breathing tests are important^[1]. This trial is designed to see whether ZAMPILIMAB can improve or preserve lung function better than placebo over 24 weeks^[1].

Because only one trial is provided in the source data, the current picture is limited to this Phase 2 study in IPF^[1]. The most important facts from the available record are the condition studied, the authorised status, the planned enrolment of 235 participants, and the focus on ppFVC at Week 24^[1].

Table of Contents

• Trial overview
• Who can participate
• What is being tested
• Study phase and design
• Outcomes being measured
• Trial status and size

Trial overview

One authorised interventional study is listed for STREPTOCOCCUS PYOGENES, and it focuses on reducing respiratory infections in children.^[1] The study title says it is designed to show the efficacy of PMBL (Ismigen) in lowering respiratory infections in children aged 3 to 12 years.^[1]

Who can participate

The target population is children aged 3 to 12 years.^[1] The study is aimed at children with respiratory tract infections, which are infections that affect the airways and lungs.^[1]

What is being tested

The trial compares PMBL (Ismigen) tablets with placebo, which is an inactive treatment used for comparison.^[1] The tablets are given by sublingual use, meaning they are used under the tongue.^[1] The main question is whether PMBL (Ismigen) can reduce the number of respiratory tract infections over the study period.^[1]

Study phase and design

This is a Phase 3 trial.^[1] Phase 3 studies usually test how well a treatment works in a larger group of people, and this study is planned as an interventional comparison between active treatment and placebo.^[1]

Outcomes being measured

The main outcome is the rate of respiratory tract infections, meaning the number of RTIs a child has during the study.^[1] This outcome is measured across a 3-month treatment period and a 4-month follow-up period.^[1] The study summary says the goal is to see whether the treatment lowers the incidence of respiratory tract infections during the whole observation period compared with placebo.^[1]

Trial status and size

The trial status is Authorised, and the planned enrollment is 224 children.^[1] This means the study has permission to run and aims to include 224 participants.^[1]

Table of Contents

• Trial overview
• Who can participate
• What is being studied
• Study design and phase
• Endpoints and what researchers measure
• Study status and enrollment

Trial overview

This clinical trial is a Phase 3 study of STREPTOCOCCUS VIRIDANS-related research in children with respiratory tract infections.^[1] The study is titled as a trial to show the efficacy of PMBL (Ismigen) in reducing respiratory infections in children aged 3 to 12 years.^[1]

Who can participate

The target population is children aged 3 to 12 years.^[1] The source data does not give more detailed entry rules, so the main known eligibility feature is age.^[1]

What is being studied

The study is looking at whether the treatment can reduce the number of respiratory tract infections during the whole observation period.^[1] It compares a study treatment with placebo, which is a look-alike treatment used for comparison.^[1]

The brief summary says the treatment is used during the fall and winter period, and the goal is to lower the incidence of respiratory tract infections compared with placebo.^[1]

Study design and phase

This is an interventional study, which means researchers give a study treatment and then measure the results.^[1] The study is in Phase 3, so it is testing the treatment in a later stage and in a larger group of participants.^[1]

The trial uses a placebo comparison and includes a treatment period followed by follow-up, allowing researchers to see both short-term and later effects.^[1]

Endpoints and what researchers measure

The primary outcome is the rate of respiratory tract infections, meaning the number of infections each child has during the study.^[1] Researchers measure this across a 3-month treatment period and a 4-month follow-up period.^[1]

This endpoint is important because it shows whether the study treatment may reduce how often children get these infections over time.^[1]

Study status and enrollment

The trial status is Authorised, which means it has been approved to proceed in the source record.^[1] The planned enrollment is 224 children.^[1]

Only one trial record was provided, so this article focuses on that study and its main research question.^[1]

Table of contents

• Trial overview
• Who is being studied
• How the trials are designed
• What the trials measure
• Target populations and treatment groups
• Patient-friendly explanation of key terms

Trial overview

Two Phase 3 clinical trials are investigating LOLIUM PERENNE POLLEN, DEPIGMENTED POLYMERIZED EXTRACT in people with pollen allergy symptoms.^[1][2]

One trial studies people with allergic rhinoconjunctivitis, with or without asthma, linked to grass and olive pollen sensitization.^[1] The other studies people with allergic rhinoconjunctivitis, with or without controlled asthma, linked to grass pollen allergy.^[2]

Who is being studied

The first study, GOES, includes people with clinically relevant sensitisation to grass and olive pollen.^[1] The condition studied is allergic rhinoconjunctivitis with or without asthma.^[1]

The second study, GIRA, includes people with allergic rhinoconjunctivitis with or without controlled asthma.^[2] This means the study is focused on patients whose asthma is already under control if they have asthma.^[2]

How the trials are designed

Both studies are interventional, which means researchers give a study treatment and then measure the results.^[1][2]

Both trials compare active treatment with placebo, which is the solvent used in the investigational product formulation and acts as a comparison treatment.^[1][2]

In the GOES study, the treatment arm includes Depigoid DUO Grass-Mix/Olea, and the study also uses conjunctival provocation tests with grass mix and Olea europaea.^[1]

In the GIRA study, the treatment arms include Depigoid Grass-Mix and Depigoid FORTE Grass-Mix, and the study also uses a conjunctival provocation test with grass mix.^[2]

What the trials measure

The main outcome in both studies is the combined symptom and medication score, also called cSMS, measured on a 0 to 6 scale during the peak pollen season.^[1][2]

This score combines allergy symptoms and the medicines used to control them.^[1][2] In the trial data, symptom items include runny nose, sneezing, itchy nose, nasal congestion, itchy eyes, and tearing.^[1]

The GOES study measures cSMS at the peak of grass and olive pollen season after at least 8 injections of treatment.^[1] The GIRA study measures cSMS at the peak of grass pollen season after at least 8 injections of treatment.^[2]

The GIRA study also has an open-label phase, where it measures the change in the amount of allergen needed to obtain a positive conjunctival provocation test after the pollen season compared with baseline.^[2]

Target populations and treatment groups

The GOES trial plans to enroll 343 participants.^[1] It focuses on people with allergy to both grass and olive pollen, with or without asthma.^[1]

The GIRA trial plans to enroll 324 participants.^[2] It focuses on people with grass pollen allergy, with or without controlled asthma.^[2]

These studies are designed to compare different treatment strengths and placebo, so researchers can see whether the active treatment improves allergy control during pollen season.^[1][2]

Patient-friendly explanation of key terms

Allergic rhinoconjunctivitis means allergy symptoms in the nose and eyes, such as sneezing, congestion, itching, and watery eyes.^[1][2]

Controlled asthma means asthma that is already managed well enough to meet the study rules.^[2]

Peak pollen season is the time when pollen levels are highest and symptoms are often worse.^[1][2]

Open-label phase means people know what treatment they are receiving.^[2]

Positive conjunctival provocation test means the eye reacts to a small amount of allergen during testing.^[2]

Table of contents

• Trial overview
• Condition and target population
• Study design and phase
• What is being measured
• Who may join the study
• Why this trial matters

Trial overview

This article covers one interventional study of SAR445399 in adults with moderate to severe hidradenitis suppurativa.^[1] The study is listed as authorised and is a Phase 2 trial with a planned enrollment of 206 participants.^[1]

Condition and target population

The trial is studying hidradenitis suppurativa (HS), a long-term skin condition, in adults who have moderate to severe disease.^[1] This means the study is focused on people whose symptoms are not mild and who may need more active treatment research options.^[1]

Study design and phase

The available data describe SAR445399 as part of a Phase 2 study.^[1] Phase 2 trials are used to learn more about whether a treatment may work and to keep checking safety in a defined patient group.^[1]

The study summary says it is evaluating different doses of SAR445399.^[1] In simple terms, the researchers are comparing amounts of the study treatment to see how well they may help people with this condition.^[1]

What is being measured

The main goal of the study is to evaluate efficacy, which means how well the treatment works for the target condition.^[1] The trial also aims to assess safety, meaning whether the treatment can be used without causing unacceptable harm in the study setting.^[1]

Because the brief summary specifically mentions efficacy of different doses, the study is likely focused on whether one dose works better than another for people with hidradenitis suppurativa.^[1]

Who may join the study

The trial data state that the study is for adult participants with moderate to severe hidradenitis suppurativa.^[1] No other eligibility details are provided in the source data, so the full set of entry rules cannot be confirmed here.^[1]

Why this trial matters

Hidradenitis suppurativa can be difficult to manage when it is moderate to severe, so studies like this one are important for finding better treatment options.^[1] This trial may help show whether SAR445399 is worth studying further in this patient group.^[1]